glp-1 news october 1 2025 dominates for trial activity New research looks at potential

Here is a quick breakdown of where the key next-generation candidates currently stand: Retatrutide (Eli Lilly): Phase 3 trials are actively studying cardiovascular outcomes alongside weight loss

This creates "rigid thinking," where one slip-up makes a person feel they have "ruined everything," triggering emotional overeating

Age and Overall Health: Younger, healthier patients typically recover faster

however, 3 were ineligible due to 1 not being resistance-trained and 2 had previously taken nutritional supplements that were included in the exclusionary criteria

Primary care clinics are overwhelmed with patient portal messages, so its important to understand what kinds of follow-up appointments youll need, and how to escalate concerns. With no non-GLP-1 options available through Bridge, those who cant tolerate any of the covered medications should talk with their prescriber about non-GLP-1 options that they could potentially pay for out of pocket